Risk factors
Definium Therapeutics (DFTX) risk factors
Item 1A of every Definium Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors87 risks8 new8 dropped17 reworded
Definium Therapeutics relies heavily on developing controlled substances like lysergide and MDMA, facing strict DEA and regulatory oversight. The company restructured its debt facility, increasing its first-tranche borrowing under the amended loan agreement to $42.0 million. Pipeline product names were updated from MM120 and MM402 to DT120 ODT and DT402.
Filed Feb 26, 2026 - FY2024 10-K risk factors87 risks
Clinical-stage biopharmaceutical company focused on developing brain health product candidates including MM120 and MM402.
Filed Mar 06, 2025